Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer

Molecular and Cellular Proteomics

Volumn 10, Issue 12, 2011, Pages

  Wu, Zhixiang ^a   Doondeea, Jessica B ^b   Gholami, Amin Moghaddas ^a   Janning, Melanie C ^b   Lemeer, Simone ^a   Kramer, Karl ^a   Eccles, Suzanne A ^c   Gollin, Susanne M ^d   Grenman, Reidar ^e   Walch, Axel ^f   Feller, Stephan M ^b   Kuster, Bernhard ^a,g  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e TURKU UNIVERSITY HOSPITAL   (Finland)

^f INSTITUTE OF EPIDEMIOLOGY   (Germany)

^g Munich Center for Integrated Protein Science   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; CYCLIN DEPENDENT KINASE 1; DASATINIB; EPHRIN RECEPTOR A1; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A4; EPHRIN RECEPTOR B3; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; JANUS KINASE 1; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEK9 PROTEIN; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE LYN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WEE1 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DRUG TARGETING; FUNCTIONAL PROTEOMICS; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA;

CARCINOMA; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; GENE KNOCKDOWN TECHNIQUES; HUMANS; JANUS KINASE 1; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPHA2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASE 2; RNA INTERFERENCE; SRC-FAMILY KINASES; TISSUE ARRAY ANALYSIS; TONGUE NEOPLASMS;

EID: 83055168499     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M111.011635     Document Type: Article

References (78)

1. Leemans, C. R., Braakhuis, B. J., and Brakenhoff, R. H. (2011) The molecular biology of head and neck cancer. Nat. Rev. Cancer 11, 9-22
2. Brennan, J. A., Boyle, J. O., Koch, W. M., Goodman, S. N., Hruban, R. H., Eby, Y. J., Couch, M. J., Forastiere, A. A., and Sidransky, D. (1995) Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 332, 712-717
3. Okami, K., Wu, L., Riggins, G., Cairns, P., Goggins, M., Evron, E., Halachmi, N., Ahrendt, S. A., Reed, A. L., Hilgers, W., Kern, S. E., Koch, W. M., Sidransky, D., and Jen, J. (1998) Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res. 58, 509-511 (Pubitemid 28087415)
4. Smeets, S. J., van der Plas, M., Schaaij-Visser, T. B., van Veen, E. A., van Meerloo, J., Braakhuis, B. J., Steenbergen, R. D., and Brakenhoff, R. H. (2011) Immortalization of oral keratinocytes by functional inactivation of the p53 and pRb pathways. Int. J. Cancer 128, 1596-1605
5. Somers, K. D., Merrick, M. A., Lopez, M. E., Incognito, L. S., Schechter, G. L., and Casey, G. (1992) Frequent p53 mutations in head and neck cancer. Cancer Res. 52, 5997-6000
6. Redon, R., Muller, D., Caulee, K., Wanherdrick, K., Abecassis, J., and du Manoir, S. (2001) A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res. 61, 4122-4129 (Pubitemid 32720980)
7. Sheu, J. J., Hua, C. H., Wan, L., Lin, Y. J., Lai, M. T., Tseng, H. C., Jinawath, N., Tsai, M. H., Chang, N. W., Lin, C. F., Lin, C. C., Hsieh, L. J., Wang, T. L., Shih, I., and Tsai, F. J. (2009) Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res. 69, 2568-2576
8. Murugan, A. K., Hong, N. T., Fukui, Y., Munirajan, A. K., and Tsuchida, N. (2008) Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int. J. Oncol. 32, 101-111 (Pubitemid 351176067)
9. Bornstein, S., White, R., Malkoski, S., Oka, M., Han, G., Cleaver, T., Reh, D., Andersen, P., Gross, N., Olson, S., Deng, C., Lu, S. L., and Wang, X. J. (2009) Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J. Clin. Invest. 119, 3408-3419
10. Hague, A., Eveson, J. W., MacFarlane, M., Huntley, S., Janghra, N., and Thavaraj, S. (2004) Caspase-3 expression is reduced, in the absence of cleavage, in terminally differentiated normal oral epithelium but is increased in oral squamous cell carcinomas and correlates with tumour stage. J. Pathol. 204, 175-182 (Pubitemid 39335291)
11. Wang, D., Song, H., Evans, J. A., Lang, J. C., Schuller, D. E., and Weghorst, C. M. (1997) Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis 18, 2285-2290 (Pubitemid 28134761)
12. Freudlsperger, C., Burnett, J. R., Friedman, J. A., Kannabiran, V. R., Chen, Z., and Van Waes, C. (2011) EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: Attractive targets for molecular-oriented therapy. Expert Opin. Ther. Targets 15, 63-74
13. Sharafinski, M. E., Ferris, R. L., Ferrone, S., and Grandis, J. R. (2010) Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32, 1412-1421
14. Zimmermann, M., Zouhair, A., Azria, D., and Ozsahin, M. (2006) The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications. Radiat. Oncol. 1, 11
15. Astsaturov, I., Cohen, R. B., and Harari, P. M. (2008) Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat. Res. 139, 135-152
16. Huang, S. M., and Harari, P. M. (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res. 6, 2166-2174
17. Mazumdar, A., Henderson, Y. C., El-Naggar, A. K., Sen, S., and Clayman, G. L. (2009) Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma. Head Neck 31, 625-634
18. Gerster, K., Shi, W., Ng, B., Yue, S., Ito, E., Waldron, J., Gilbert, R., and Liu, F. F. (2010) Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 77, 253-260
19. Seiwert, T. Y., Jagadeeswaran, R., Faoro, L., Janamanchi, V., Nallasura, V., El Dinali, M., Yala, S., Kanteti, R., Cohen, E. E., Lingen, M. W., Martin, L., Krishnaswamy, S., Klein-Szanto, A., Christensen, J. G., Vokes, E. E., and Salgia, R. (2009) The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 69, 3021-3031
20. Bantscheff, M., Schirle, M., Sweetman, G., Rick, J., and Kuster, B. (2007) Quantitative mass spectrometry in proteomics: A critical review. Anal. Bioanal. Chem. 389, 1017-1031 (Pubitemid 47482251)
21. Mallick, P., and Kuster, B. (2010) Proteomics: A pragmatic perspective. Nat. Biotechnol. 28, 695-709
22. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (Pubitemid 47517638)
23. Bantscheff, M., Hopf, C., Kruse, U., and Drewes, G. (2007) Proteomics-based strategies in kinase drug discovery. Ernst Schering Found. Symp. Proc. 2007, 1-28
24. Patel, V. J., Thalassinos, K., Slade, S. E., Connolly, J. B., Crombie, A., Murrell, J. C., and Scrivens, J. H. (2009) A comparison of labeling and label-free mass spectrometry-based proteomics approaches. J. Proteome Res. 8, 3752-3759
25. Kruse, U., Pallasch, C. P., Bantscheff, M., Eberhard, D., Frenzel, L., Ghidelli, S., Maier, S. K., Werner, T., Wendtner, C. M., and Drewes, G. (2011) Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells. Leukemia 25, 89-100
26. Edington, K. G., Loughran, O. P., Berry, I. J., and Parkinson, E. K. (1995) Cellular immortality: A late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss. Mol. Carcinog. 13, 254-265
27. Eicheler, W., Zips, D., Dörfler, A., Grénman, R., and Baumann, M. (2002) Splicing mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection. J. Histochem. Cytochem. 50, 197-204 (Pubitemid 34106758)
28. Gioanni, J., Fischel, J. L., Lambert, J. C., Demard, F., Mazeau, C., Zanghellini, E., Ettore, F., Formento, P., Chauvel, P., Lalanne, C. M., and Courdi, A. (1988) Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: Establishment, characterization and response to cytotoxic treatment. Eur. J. Cancer Clin. Oncol. 24, 1445-1455
29. Järvinen, A. K., Autio, R., Kilpinen, S., Saarela, M., Leivo, I., Grénman, R., Mäkitie, A. A., and Monni, O. (2008) High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. Genes Chromosomes Cancer 47, 500-509 (Pubitemid 351657185)
30. Kawashiri, S., Kumagai, S., Kojima, K., Harada, H., and Yamamoto, E. (1995) Development of a new invasion and metastasis model of human oral squamous cell carcinomas. Eur. J. Cancer B Oral. Oncol. 31B, 216-221
31. Lansford, C. D., Grenman, R., Bier, H., Somers, K. D., Kim, S. Y., Whiteside, T. L., Clayman, G. L., Welkoborsky, H. J., and Carey, T. E. (1999) Human Cell Culture, Cancer Cell Lines. In Head and Neck Cancers (Masters, J., and Palsson, B., eds.) pp. 185-255, Kluwer Academic Press, Dordrecht, The Netherlands
32. Lin, C. J., Grandis, J. R., Carey, T. E., Gollin, S. M., Whiteside, T. L., Koch, W. M., Ferris, R. L., and Lai, S. Y. (2007) Head and neck squamous cell carcinoma cell lines: Established models and rationale for selection. Head Neck 29, 163-188 (Pubitemid 46167784)
33. Momose, F., Araida, T., Negishi, A., Ichijo, H., Shioda, S., and Sasaki, S. (1989) Variant sublines with different metastatic potentials selected in nude mice from human oral squamous cell carcinomas. J. Oral Pathol. Med. 18, 391-395 (Pubitemid 20001923)
34. O-charoenrat, P., Modjtahedi, H., Rhys-Evans, P., Court, W. J., Box, G. M., and Eccles, S. A. (2000) Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res. 60, 1121-1128
35. Pekkola-Heino, K., Joensuu, H., Klemi, P., and Grenman, R. (1994) Relation of DNA ploidy and proliferation rate to radiation sensitivity in squamous carcinoma cell lines. Arch. Otolaryngol. Head Neck Surg. 120, 750-754 (Pubitemid 24217589)
36. Pekkola-Heino, K., Kulmala, J., Klemi, P., Lakkala, T., Aitasalo, K., Joensuu, H., and Grenman, R. (1991) Effects of radiation fractionation on four squamous cell carcinoma lines with dissimilar inherent radiation sensitivity. J. Cancer Res. Clin. Oncol. 117, 597-602
37. Dos Reis, P. P., Bharadwaj, R. R., Machado, J., Macmillan, C., Pintilie, M., Sukhai, M. A., Perez-Ordonez, B., Gullane, P., Irish, J., and Kamel-Reid, S. (2008) Claudin 1 overexpression increases invasion and is associated with aggressive histological features in oral squamous cell carcinoma. Cancer 113, 3169-3180
38. Rheinwald, J. G., and Beckett, M. A. (1981) Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res. 41, 1657-1663 (Pubitemid 11114553)
39. White, J. S., Weissfeld, J. L., Ragin, C. C., Rossie, K. M., Martin, C. L., Shuster, M., Ishwad, C. S., Law, J. C., Myers, E. N., Johnson, J. T., and Gollin, S. M. (2007) The influence of clinical and demographic risk factors on the establishment of head and neck squamous cell carcinoma cell lines. Oral Oncol. 43, 701-712 (Pubitemid 47058372)
40. Yoshida, H., Hasegawa, S., Kuromi, H., Inagaki, N., Seino, S., Takahashi, K., and Sato, K. (1993) A variant form of laminin is responsible for the neurite outgrowth-promoting activity in conditioned medium from a squamous carcinoma cell line. Connect. Tissue Res. 30, 23-35 (Pubitemid 2019911)
41. Zhang, N., Erjala, K., Kulmala, J., Qiu, X., Sundvall, M., Elenius, K., and Grénman, R. (2009) Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother. Oncol. 92, 388-392
42. Eng, C., Thiele, H., Zhou, X. P., Gorlin, R. J., Hennekam, R. C., and Winter, R. M. (2001) PTEN mutations and proteus syndrome. Lancet 358, 2079-2080
43. Hauck, S. M., Dietter, J., Kramer, R. L., Hofmaier, F., Zipplies, J. K., Amann, B., Feuchtinger, A., Deeg, C. A., and Ueffing, M. (2010) Deciphering membrane-associated molecular processes in target tissue of autoimmune uveitis by label-free quantitative mass spectrometry. Mol. Cell Proteomics 9, 2292-2305
44. Huber, W., von Heydebreck, A., Sultmann, H., Poustka, A., and Vingron, M. (2002) Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 1, (Suppl. 18) S96-S104 (Pubitemid 41185642)
45. Karp, N. A., Huber, W., Sadowski, P. G., Charles, P. D., Hester, S. V., and Lilley, K. S. (2010) Addressing accuracy and precision issues in iTRAQ quantitation. Mol. Cell Proteomics 9, 1885-1897
46. Smyth, G. K. (2004) Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3
47. Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry, R., Leisch, F., Li, C., Maechler, M., Rossini, A. J., Sawitzki, G., Smith, C., Smyth, G., Tierney, L., Yang, J. Y., and Zhang, J. (2004) Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol. 5, R80
48. Benjamini, Y., and Hochberg, Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Methodol. 57, 289-300
49. Rauser, S., Langer, R., Tschernitz, S., Gais, P., Jütting, U., Feith, M., Höfler, H., and Walch, A. (2010) High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. BMC Cancer 10, 608
50. Fang, R., Elias, D. A., Monroe, M. E., Shen, Y., McIntosh, M., Wang, P., Goddard, C. D., Callister, S. J., Moore, R. J., Gorby, Y. A., Adkins, J. N., Fredrickson, J. K., Lipton, M. S., and Smith, R. D. (2006) Differential label-free quantitative proteomic analysis of Shewanella oneidensis cultured under aerobic and suboxic conditions by accurate mass and time tag approach. Mol. Cell Proteomics 5, 714-725
51. Wykosky, J., Gibo, D. M., and Debinski, W. (2007) A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. Mol. Cancer Ther. 6, 3208-3218
52. Pratt, R. L., and Kinch, M. S. (2002) Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene 21, 7690-7699 (Pubitemid 35398815)
53. Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A., Das, J., Doweyko, A. M., Fairchild, C., Hunt, J. T., Inigo, I., Johnston, K., Kamath, A., Kan, D., Klei, H., Marathe, P., Pang, S., Peterson, R., Pitt, S., Schieven, G. L., Schmidt, R. J., Tokarski, J., Wen, M. L., Wityak, J., and Borzilleri, R. M. (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2- methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658-6661 (Pubitemid 40053752)
54. Pearson, M. A., and Fabbro, D. (2004) Targeting protein kinases in cancer therapy: A success? Expert Rev. Anticancer Ther. 4, 1113-1124 (Pubitemid 39646565)
55. Cruz, J. J., Ocaña, A., Del Barco, E., and Pandiella, A. (2007) Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann. Oncol. 18, 421-430 (Pubitemid 46359619)
56. McDermott, U., and Settleman, J. (2009) Personalized cancer therapy with selective kinase inhibitors: An emerging paradigm in medical oncology. J. Clin. Oncol. 27, 5650-5659
57. Fishman, M. C., and Porter, J. A. (2005) Pharmaceuticals: A new grammar for drug discovery. Nature 437, 491-493 (Pubitemid 41613538)
58. Maurizi, M., Almadori, G., Ferrandina, G., Distefano, M., Romanini, M. E., Cadoni, G., Benedetti-Panici, P., Paludetti, G., Scambia, G., and Mancuso, S. (1996) Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br. J. Cancer 74, 1253-1257 (Pubitemid 26360115)
59. Weinstein, I. B. (2002) Cancer: Addiction to oncogenes: The Achilles heal of cancer. Science 297, 63-64
60. Bischoff, J. R., and Plowman, G. D. (1999) The Aurora/Ipl1p kinase family: Regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 9, 454-459 (Pubitemid 29469430)
61. Inohara, N., del Peso, L., Koseki, T., Chen, S., and Núñez, G. (1998) RICK, a novel protein kinase containing a caspase recruitment domain, interacts with CLARP and regulates CD95-mediated apoptosis. J. Biol. Chem. 273, 12296-12300 (Pubitemid 28240597)
62. Wykosky, J., Gibo, D. M., Stanton, C., and Debinski, W. (2005) EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3, 541-551 (Pubitemid 41567273)
63. Landen, C. N., Kinch, M. S., and Sood, A. K. (2005) EphA2 as a target for ovarian cancer therapy. Expert Opin. Ther. Targets 9, 1179-1187 (Pubitemid 41762872)
64. Duxbury, M. S., Ito, H., Zinner, M. J., Ashley, S. W., and Whang, E. E. (2004) EphA2: A determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23, 1448-1456 (Pubitemid 38406840)
65. Brannan, J. M., Dong, W., Prudkin, L., Behrens, C., Lotan, R., Bekele, B. N., Wistuba, I., and Johnson, F. M. (2009) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin. Cancer Res. 15, 4423-4430
66. Rivera, R. S., Gunduz, M., Nagatsuka, H., Gunduz, E., Cengiz, B., Fukushima, K., Beder, L. B., Pehlivan, D., Yamanaka, N., Shimizu, K., and Nagai, N. (2008) Involvement of EphA2 in head and neck squamous cell carcinoma: mRNA expression, loss of heterozygosity and immunohistochemical studies. Oncol. Rep. 19, 1079-1084
67. Shao, Z., Zhang, W. F., Chen, X. M., and Shang, Z. J. (2008) Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: Correlation with the angiogenesis and clinical outcome. Oral Oncol. 44, 1110-1117
68. Wykosky, J., and Debinski, W. (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: Function and therapeutic targeting. Mol. Cancer Res. 6, 1795-1806
69. Gene Expression Atlas: ArrayExpress database: http://www.ebi.ac.uk/gxa under accession number E-MTAB-62
70. Pardanani, A., Lasho, T., Smith, G., Burns, C. J., Fantino, E., and Tefferi, A. (2009) CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 23, 1441-1445
71. Goldenberg-Furmanov, M., Stein, I., Pikarsky, E., Rubin, H., Kasem, S., Wygoda, M., Weinstein, I., Reuveni, H., and Ben-Sasson, S. A. (2004) Lyn is a target gene for prostate cancer: Sequence-based inhibition induces regression of human tumor xenografts. Cancer Res. 64, 1058-1066 (Pubitemid 38176910)
72. Tourret, J., and McKeon, F. (1996) Tyrosine kinases wee1 and mik1 as effectors of DNA replication checkpoint control. Prog. Cell Cycle Res. 2, 91-97
73. PosthumaDeBoer, J., Wrdinger, T., Graat, H. C., van Beusechem, V. W., Helder, M. N., van Royen, B. J., and Kaspers, G. J. (2011) WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 11, 156
74. Schwartz, D. L., and Dong, L. (2011) Adaptive radiation therapy for head and neck cancer-can an old goal evolve into a new standard? J. Oncol. 2011
75. Kim, L. C., Song, L., and Haura, E. B. (2009) Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 6, 587-595
76. Song, L., Morris, M., Bagui, T., Lee, F. Y., Jove, R., and Haura, E. B. (2006) Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. 66, 5542-5548 (Pubitemid 43927102)
77. Christensen, J. G., Schreck, R., Burrows, J., Kuruganti, P., Chan, E., Le, P., Chen, J., Wang, X., Ruslim, L., Blake, R., Lipson, K. E., Ramphal, J., Do, S., Cui, J. J., Cherrington, J. M., and Mendel, D. B. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 63, 7345-7355 (Pubitemid 37413476)
78. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844-847 (Pubitemid 28331029)